People with allergic fungal rhinosinusitis taking Dupixent (dupilumab) saw significant improvement in congestion and sinus ...

The FDA approved Dupixent as the first treatment for allergic fungal rhinosinusitis in adults and children over six years old ...

The FDA has approved dupilumab to treat allergic fungal rhinosinusitis in adults and children ages 6 years and older.

Hurst took a break in 2024 following advice from Bolton GP Federation nurse Emma Walker, however, only for her assertion to be countered a month later by her GP, Dr Moyinoluwa Oluwaseyi Onayade, who ...

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and ...

Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitisApproval in adults and ...

The community has rallied round the family of a Hastings man, who is battling a rare form of cancer.

Our findings suggest that GLP-1 therapy holds real promise. While a randomized trial is still needed, the fact that many patients with IIH already qualify for GLP-1s due to diabetes or obesity means ...

Early symptoms that mimic common ear and sinus conditions often lead to delayed diagnosis.

Eli Lilly and Company and Incyte announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Olumiant ...

More than 80% of those treated with TREMFYA® were in clinical remission and more than 50% were in endoscopic remission at Week 140 of the QUASAR long-term ...